



**In Support of Amendments to Maryland S528
Climate Solutions Now Act of 2022
March 23, 2022**

Position: The Pharmaceutical Research and Manufacturers of America (PhRMA) respectfully supports Maryland Tech Council's ("MTC") proposed amendments to Senate Bill 528, which aligns the bill language with current state code.

PhRMA represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested nearly \$1 trillion in the search for new treatments and cures, including an estimated \$91.1 billion in 2020 alone.

Many PhRMA members actively strive for what Senate Bill 528 seeks to achieve regarding lowering greenhouse gas emissions with the goal of reaching net zero. With this said, laboratories and research facilities associated with essential clinical research require continuous sources of power to function. Mandating that these facilities rely solely on an electrical grid, sans natural gas and/or diesel generators for security against power interruption, could result in great product and data losses in the event the power grid failed.

PhRMA asks that the General Assembly adopt the proposed amendments by MTC that includes the exclusion of buildings used in life sciences as defined in 3-206 of the Economic Development Article.

PhRMA appreciates your consideration of our request.